Clinical value of adding Dapagliflozin in patients with nephrotic syndrome
International Urology and Nephrology · 2024
DOI: 10.1007/s11255-024-04099-1 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Urology and Nephrology, 2024. Verfasst von Magdy ElSharkawy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Internal Medicine and Nephrology Department, Ain Shams University, Ramsis Street 38, Abbasia, Cairo, Postal Code: 11566, Egypt. Hauptthemen laut MEDLINE: Nephrotic Syndrome, Glucosides, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors in nephrotic patients on immunosuppression are underexplored. We evaluated dapagliflozin's impact in non-diabetic primary nephrotic syndrome. METHODS: Randomized controlled clinical trial was conducted on 60 non-diabetic primary nephrotic syndrome patients, equally assigned to dapagliflozin and control groups. All patients received the standard of care medication and the Dapagliflozin group received 10 mg dapagliflozin in addition. Demographic data, nephrotic syndrome etiology, proteinuria levels, eGFR, and immunosuppression doses, were well-matched. After 6 months of follow up primary outcomes included changes in and eGFR. RESULTS: Both groups exhibited significant reductions in proteinuria after 6 months, with the dapagliflozin group achieving a mean UPCR reduction of - 94.7%, and the control group - 86.7% (p < 0.001). However, the comparative change in proteinuria between both groups did not reach statistical significance (p = 0.158). Dapagliflozin initially led to a transient eGFR decline. Dapagliflozin also resulted in a significant mean body weight reduction (p < 0.001) and notable improvements in triglyceride levels compared to the control group (p = 0.045). CONCLUSION: In primary nephrotic syndrome patients, adjunct dapagliflozin may enhance the standard of care. While notable, the reduction in proteinuria was comparable to that of the control group by the study's end. Furthermore, after 6 months, eGFR remained stable in both groups. However, significant weight loss and serum triglyceride reduction were particularly pronounced in the dapagliflozin group. Further long-term investigations are necessary to address potential immunosuppression-related confounding effects in patients with primary glomerular disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Internal Medicine and Nephrology Department, Ain Shams University, Ramsis Street 38, Abbasia, Cairo, Postal Code: 11566, Egypt.
- Faculty of Medicine, Medical Physiology Department, Ain Shams University, Cairo, Egypt.
- Faculty of Medicine, Internal Medicine and Nephrology Department, Ain Shams University, Ramsis Street 38, Abbasia, Cairo, Postal Code: 11566, Egypt. nahlateama@med.asu.edu.eg.
Zitieren
APA
ElSharkawy, M., Emara, A., Ahmed, M. M., Ghonamy, E., & Teama, N. M. (2024). Clinical value of adding Dapagliflozin in patients with nephrotic syndrome. International Urology and Nephrology. https://doi.org/10.1007/s11255-024-04099-1
Vancouver
ElSharkawy M, Emara A, Ahmed MM, Ghonamy E, Teama NM. Clinical value of adding Dapagliflozin in patients with nephrotic syndrome. International Urology and Nephrology. 2024. doi:10.1007/s11255-024-04099-1
BibTeX
@article{ElSharkawy2024,
author = {ElSharkawy, Magdy and Emara, Ahmed and Ahmed, Mohamed Mohyeldin and Ghonamy, ElSayed and Teama, Nahla Mohamed},
title = {Clinical value of adding Dapagliflozin in patients with nephrotic syndrome},
journal = {International Urology and Nephrology},
year = {2024},
doi = {10.1007/s11255-024-04099-1}
}
EUVIMED